SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN

MADISON, Wis. , Aug. 19, 2024 /PRNewswire/ -- BioVaxys Technology Corp.

(CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF ) ("BioVaxys") and SpayVac for Wildlife, Inc. ("SpayVac") jointly announce that SpayVac® recently completed set-up of its new research and production facility in Madison, Wisconsin to produce their long-lasting, single-dose veterinary contraceptive vaccines. SpayVac® uses a patented liposome-based antigen delivery platform technology, licensed from BioVaxys ( https://www.

biovaxys.com/ ), which has demonstrated a robust and sustained immune response in several species. SpayVac single-dose vaccines will address the fertility-control needs in wildlife, agricultural production animals, and aquaculture markets.

SpayVac for Wildlife, Inc. initially operated out of the University of Victoria, British Columbia , and relocated to Madison, Wisconsin , after the pandemic. With support from the BrightStar Wisconsin Foundation and angel investors, SpayVac was able to expand its laboratory and lease space in a building owned by Lytic Solutions, which will allow the company to produce vaccines for ongoing and future experimental contraceptive trials.

"This new laboratory will significantly enhance our ability to develop new vaccine formulations for species that would benefit from humane, long-term fertility control," said Dr. Ursula Bechert , Vice-President of Research and Development for SpayVac for Wildlife. Tom D'Orazio, CEO of SpayVac for Wildlife, shared, "I'm enthusiastic abo.